Gain Gross Profit from 2010 to 2024

GANX Stock

USD 1.86 0.12 6.90%

Gain Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about -26.5 K in 2024. Gross Profit is the profit Gain Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2018-03-31

Previous Quarter

-20.5 K

Current Value

-20.6 K

Quarterly Volatility

36.1 K

Covid

Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 150 K, Net Interest Income of 579.3 K or Depreciation And Amortization of 44.3 K, as well as many indicators such as Price To Sales Ratio of 733, Dividend Yield of 0.0 or PTB Ratio of 3.55. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.

Check out the analysis of Gain Therapeutics Correlation against competitors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Gain Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Gain Therapeutics minus its cost of goods sold. It is profit before Gain Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Gain Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (7.66 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Gain Gross Profit Regression Statistics

	Arithmetic Mean	(598,567)
	Geometric Mean	48,906
	Coefficient Of Variation	(311.28)
	Mean Deviation	1,070,990
	Median	20,609
	Standard Deviation	1,863,216
	Sample Variance	3.5T
	Range	7.1M
	R-Value	(0.30)
	Mean Square Error	3.4T
	R-Squared	0.09
	Significance	0.28
	Slope	(125,423)
	Total Sum of Squares	48.6T

Gain Gross Profit History

	2024	-26.5 K
	2023	-25.2 K
	2022	75.9 K
	2021	-7 M
	2020	-2.2 M
	2019	41.3 K

Other Fundumenentals of Gain Therapeutics

Gross Profit Margin

Gain Therapeutics Gross Profit component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Long Term Debt	Short Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.71	0.67	0.99	0.91	0.48	0.98	0.97	0.22	-0.92	0.87	0.97	0.89	0.97	0.99	-0.77	0.91	-0.16	-0.34	-0.34
Retained Earnings	-0.72		-0.82	-0.97	-0.67	-0.9	0.2	-0.71	-0.65	-0.71	0.49	-0.91	-0.66	-0.91	-0.65	-0.74	0.99	-0.92	0.58	0.81	0.81
Accounts Payable	0.71	-0.82		0.7	0.68	0.85	-0.1	0.71	0.65	0.26	-0.42	0.94	0.66	0.9	0.63	0.67	-0.83	0.82	-0.15	-0.43	-0.43
Net Receivables	0.67	-0.97	0.7		0.63	0.83	-0.14	0.66	0.61	0.83	-0.52	0.84	0.62	0.86	0.61	0.7	-0.93	0.85	-0.73	-0.9	-0.9
Total Current Assets	0.99	-0.67	0.68	0.63		0.86	0.53	1.0	1.0	0.16	-0.94	0.83	1.0	0.85	0.99	0.99	-0.73	0.88	-0.17	-0.32	-0.32
Common Stock	0.91	-0.9	0.85	0.83	0.86		0.11	0.87	0.83	0.44	-0.71	0.96	0.83	0.97	0.82	0.9	-0.92	0.98	-0.25	-0.51	-0.51
Property Plant Equipment	0.48	0.2	-0.1	-0.14	0.53	0.11		0.48	0.53	-0.34	-0.73	0.07	0.53	0.13	0.56	0.45	0.16	0.08	0.2	0.31	0.31
Total Assets	0.98	-0.71	0.71	0.66	1.0	0.87	0.48		1.0	0.19	-0.92	0.85	1.0	0.87	0.99	0.99	-0.77	0.9	-0.22	-0.38	-0.38
Total Stockholder Equity	0.97	-0.65	0.65	0.61	1.0	0.83	0.53	1.0		0.14	-0.94	0.8	1.0	0.82	1.0	0.98	-0.72	0.86	-0.2	-0.33	-0.33
Current Deferred Revenue	0.22	-0.71	0.26	0.83	0.16	0.44	-0.34	0.19	0.14		-0.16	0.43	0.15	0.48	0.16	0.28	-0.62	0.45	-0.86	-0.91	-0.91
Net Debt	-0.92	0.49	-0.42	-0.52	-0.94	-0.71	-0.73	-0.92	-0.94	-0.16		-0.65	-0.94	-0.7	-0.96	-0.93	0.54	-0.72	0.21	0.26	0.26
Total Liab	0.87	-0.91	0.94	0.84	0.83	0.96	0.07	0.85	0.8	0.43	-0.65		0.81	0.99	0.8	0.85	-0.92	0.94	-0.3	-0.56	-0.56
Net Invested Capital	0.97	-0.66	0.66	0.62	1.0	0.83	0.53	1.0	1.0	0.15	-0.94	0.81		0.83	1.0	0.98	-0.73	0.87	-0.2	-0.34	-0.34
Capital Stock	0.89	-0.91	0.9	0.86	0.85	0.97	0.13	0.87	0.82	0.48	-0.7	0.99	0.83		0.82	0.87	-0.91	0.94	-0.34	-0.58	-0.58
Net Working Capital	0.97	-0.65	0.63	0.61	0.99	0.82	0.56	0.99	1.0	0.16	-0.96	0.8	1.0	0.82		0.98	-0.71	0.85	-0.21	-0.34	-0.34
Short Term Debt	0.99	-0.74	0.67	0.7	0.99	0.9	0.45	0.99	0.98	0.28	-0.93	0.85	0.98	0.87	0.98		-0.8	0.92	-0.26	-0.42	-0.42
Long Term Debt	-0.77	0.99	-0.83	-0.93	-0.73	-0.92	0.16	-0.77	-0.72	-0.62	0.54	-0.92	-0.73	-0.91	-0.71	-0.8		-0.96	0.51	0.75	0.75
Short Long Term Debt	0.91	-0.92	0.82	0.85	0.88	0.98	0.08	0.9	0.86	0.45	-0.72	0.94	0.87	0.94	0.85	0.92	-0.96		-0.34	-0.58	-0.58
Intangible Assets	-0.16	0.58	-0.15	-0.73	-0.17	-0.25	0.2	-0.22	-0.2	-0.86	0.21	-0.3	-0.2	-0.34	-0.21	-0.26	0.51	-0.34		0.94	0.94
Long Term Debt Total	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94		1.0
Capital Surpluse	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94	1.0

Click cells to compare fundamentals

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-25.2 K	-26.5 K
Gross Profit Margin	(0.46)	(0.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC